Hormones and dry eye syndrome: an update on what we do and don't know

被引:42
|
作者
Rocha, Eduardo Melani [1 ]
Mantelli, Flavio [2 ]
Nominato, Luis Fernando [1 ]
Bonini, Stefano [3 ]
机构
[1] Univ Sao Paulo, BR-14049 Ribeirao Preto, SP, Brazil
[2] Univ Rome, IRCCS Fdn GB Bietti, Rome, Italy
[3] Univ Rome, Dept Ophthalmol, Rome, Italy
基金
巴西圣保罗研究基金会;
关键词
androgen; estrogen; gene therapy; insulin; lacrimal gland; sex hormone therapy; thyroid hormone; HUMAN MEIBOMIAN GLAND; OCULAR SURFACE; SJOGRENS-SYNDROME; SALIVARY-GLANDS; TEAR FUNCTION; GRAVES OPHTHALMOPATHY; THYROID-DISEASE; LACRIMAL GLAND; REPLACEMENT THERAPY; INSULIN;
D O I
10.1097/ICU.0b013e32836227bf
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose of reviewDry eye syndrome (DES) prevalence is large and its relationship with hormonal diseases is becoming clearer, although more complex. This review provides insight to this association as well as clarifying what remains unanswered about how to interpret and treat findings common to both DES and hormonal diseases.Recent findingsSeveral sex hormone-related diseases are associated with DES. Hormone replacement therapy to correct such conditions has conflicting outcomes based on epidemiologic studies and clinical trials. Thyroid-associated diseases are frequently involved in DES and must be investigated in cases where the cause of the ocular disease is undetermined. Diabetes mellitus is one of the major causes of DES, whereas correcting the metabolic imbalance minimizes its ocular symptomology. Gene therapy to treat DES-related hormonal diseases is a promising option based on animal studies.SummaryDiagnosis and management of hormonal diseases can minimize the ocular surface damage and severity of DES. Clinical care of DES includes patient evaluation of hormonal status. Future research requires clarification of the underlying disease mechanisms and identifying novel strategies to reprogram the endocrine system rather than chronic medication usage.
引用
收藏
页码:348 / 355
页数:8
相关论文
共 39 条
  • [31] Preventing Harm During Treatment of Acute Kidney Injury: What Do We Really Know?
    Hofmann, R. Michael
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2012, 19 (03) : 142 - 148
  • [32] HIV Gene Therapy Strategies and Safety: What do we know from the Recent Publications?
    Zaongo, Silvere D.
    Xia, Huan
    Ma, Ping
    AIDS REVIEWS, 2020, 22 (04) : 195 - 202
  • [33] What do we know about the role of menopause in cardiovascular autonomic regulation in hypertensive women?
    Philbois, Stella V.
    Facioli, Tabata P.
    De Lucca, Izabella
    Veiga, Ana C.
    Chinellato, Naiara
    Simoes, Marcus V.
    Tank, Jens
    Souza, Hugo C. D.
    MENOPAUSE-THE JOURNAL OF THE MENOPAUSE SOCIETY, 2024, 31 (05): : 408 - 414
  • [34] What do we know about sex differences in depression: A review of animal models and potential mechanisms
    Ma, Lei
    Xu, Yong
    Wang, Gang
    Li, Rena
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2019, 89 : 48 - 56
  • [35] Do we need to know more about the effects of hormones on lower urinary tract dysfunction? ICI-RS 2014
    Hanna-Mitchell, Ann T.
    Robinson, Dudley
    Cardozo, Linda
    Everaert, Karel
    Petkov, Georgi V.
    NEUROUROLOGY AND URODYNAMICS, 2016, 35 (02) : 299 - 303
  • [36] What you don't know can hurt you: more information and communication are needed regarding menopausal therapies
    Crawford, Sybil L.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2017, 24 (10): : 1116 - 1117
  • [37] 'Insulin is super dangerous if you don't know what you're doing': Situating the risks of insulin within the image and performance enhancing drug community
    Piatkowski, Timothy
    Cox, Luke Thomas Joseph
    DRUG AND ALCOHOL REVIEW, 2024, 43 (07) : 1976 - 1984
  • [38] A cohort study of T helper 17 cell-related cytokine levels in tear samples of systemic lupus erythematosus and Sjogren's syndrome patients with dry eye disease
    Peng, X.
    Lu, Y.
    Wei, J.
    Lin, T.
    Lu, Q.
    Liu, Q.
    Ting, W-J
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (06) : S159 - S165
  • [39] International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)? The unmet needs and the clinical grey zone in autoimmune disease management
    Giacomelli, Roberto
    Afeltra, Antonella
    Alunno, Alessia
    Baldini, Chiara
    Bartoloni-Bocci, Elena
    Berardicurti, Onorina
    Carubbi, Francesco
    Cauli, Alberto
    Cervera, Ricard
    Ciccia, Francesco
    Cipriani, Paola
    Conti, Fabrizio
    De Vita, Salvatore
    Di Benedetto, Paola
    Doria, Andrea
    Drosos, Alexandros A.
    Favalli, Ennio Giulio
    Gandolfo, Saviana
    Gatto, Mariele
    Grembiale, Rosa Daniela
    Liakouli, Vasiliki
    Lories, Rik
    Lubrano, Ennio
    Lunardi, Claudio
    Margiotta, Domenico Paolo Emanuele
    Massaro, Laura
    Meroni, Pierluigi
    Minniti, Antonia
    Navarini, Luca
    Pendolino, Monica
    Perosa, Federico
    Pers, Jacques-Olivier
    Prete, Marcella
    Priori, Roberta
    Puppo, Francesco
    Quartuccio, Luca
    Ruffatti, Amelia
    Ruscitti, Piero
    Russo, Barbara
    Sarzi-Puttini, Piercarlo
    Shoenfeld, Yehuda
    Somarakis, George A.
    Spinelli, Francesca Romana
    Tinazzi, Elisa
    Triolo, Giovanni
    Ursini, Francesco
    Valentini, Gabriele
    Valesini, Guido
    Vettori, Serena
    Vitali, Claudio
    AUTOIMMUNITY REVIEWS, 2017, 16 (09) : 911 - 924